Dataset ID: 8

Back to List

Dataset Details

Study Design
Study Design Background
Synthesis and labelling with F-18 of (2S,4R)-4-fluoroglutamine (4-FGln). In vitro evaluation using two cancers cell line and in vivo imaging in a multiple myeloma mouse model, in comparison to 18F-FDG. Evaluation of Bortezomib treatment efficacy.
Study Description
Chemical synthesis and characterization of 4-FGln. In vitro and in vivo evaluation by PET-CT of the new radiotracer [18F]4-FGln in the multiple myeloma detection and treatment. Comparison to [18F]FDG
Study Type
Preclinical
Study Subtype
In vivo and ex-vivo
Publication
Paper Linked
Yes
Paper Title
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma
Paper Authors
Valtorta S, Toscani D, Chiu M,…Moresco RM, … and Giuliani N
Affiliation
University of Milano - Bicocca, University of Parma, IRCCS San Raffale of Milan, IBFM-CNR, Italy
Paper Journal
Frontiers in Oncology
Paper Year
2021
Paper DOI
Open Access
Yes
Study Component
Multi Modality Images
Not
Imaging Modality
Radiation
Yes
Imaging Coverage
PET- whole body
Imaging Target
Glutamine and glucose metabolism
Dataset Information
Institution
IBFM-CNR
PI
Moresco Rosa Maria
Co PI
Valtorta Silvia
Country Of Institution
Italy
Imaging Facility
Laboratory of molecular imaging for small animal
Euro Bio Imaging Node
MMMI
Country Of Imaging Facility
Italy
In Vivo Experimental Parameters
Number Of Groups
2 tumor models- asyngeneic model (murine Vk12598 cells) and a xenograft model (JJN3 cells). JJN3 used also for treatment response.
Types Of Groups
1. syngeneic model (murine Vk12598 cells) for tracer biodistribution 2. xenograft model (JJN3 cells) for kinetic and biodistribution 3. JJN3 xenograft model control group (treated with vehicle) 4. JJN3 xenograft model control group (treated with Bortezomib)
Overall Sample Size
27
Disease Model
Multiple myeloma
Organ Or Tissue
Total body
Sample Size For Each Group
Group 1- 5; group 2- 7; group 3- 8; group 4- 7.
Power Calculation
G*power
Randomization
Mice were randomly assigned to control or treated group
Blinding
No
Outcome Measures
Relative tumor growth, weight loss, general well being of the mice
Statistical Methods
Unpaired t test and Wilcoxon matched-pairs signed rank-test and Unpaired Mann-Whitney test.
Species
Strain
C57BL 6J, NOD.SCID
Immune Status
Immunecompetent and immunodeficient
Sex
Female
Age
Older than 6 weeks
Age At Start Experiment
Older than 6 weeks
Age At Scanning Experiment S
Older than 6 weeks
Weight
About 25 g
Weight At Start Experiment
About 25 g
Weight At End Experiment
About 25 g
Source Of Animals
Charles river Laboratories
Registry Number Of Animal Authorization
34 2018-PR
Experimental Procedures
Pharmacological Drug
Bortezomib
Company
N.a.
Formulation
Solution
Drug Dose
1
Volume
0,03
Concentration
1 mg ml
Site Or Route Of Administration
Intravenous
Frequency Of Administration
Two times (d0 and d4)
Vehicle Or Carrier Solution Formulation
Saline
Drug Or Batch Sample Number
N.a.
Blood Sampling
Yes
Blood Sampling Method
Retroorbital bleeding
Blood Sample Volume
50 ul
Blood Timing
One a week for 3 weeks in the syngeneic model
Surgical Procedures Including Sham Surgery
No
Pathogen Infection Intervention And Control
No
Analgesic Plan To Relieve Pain Suffering And Distress
No
Anesthesia Type
Gas
Duration
30
Anesthesia Drugs
Isofluran
Anesthesia Dose
2% in 1L per minute air mix
Monitoring Regime
Software remote control of the animal's vital functions (temperature, heartbeat and breathing)
Euthanasia
Yes
Method
CO2 plus cervical dislocation
Histology
No
Frequency Of Imaging
2-3 time point for both radioligands
Timing Of Imaging
Cell line Vk12598: three time points (1 per week after cells injection); cell line JJN3: two time points (one and two weeks and before and after treatment)
Overall Scan Length
90 min for PET-CT kinetic of [18F]4-FGln; 30 minutes for PET-CT biodistribution and therapy response
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule
Yes
Contrast Agent Commercial Drug
[18F]4-FGln; [18F]FDG
Contrast Agent Chemical Drug
18F-(2S,4R)-4-fluoroglutamine; 18F-fluorodeoxyglucose
Contrast Agent Dose
4.32 ± 0.23MBq; 4.46 ± 0.41 MBq
Injection Volume
0,03
Injection Time
Scanning 15 and 60 minutes from tracer injection
Vehicle
Saline
Route Of Administration
Intravenous
Cell Line
Vk12598 cells (cell line 1); JJN3 HMCL cells (cell line 2)
Provenance
Leibniz Institute Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig,Germany) and from Vk*MYC transgenic mouse
Cell Injection Route
Vk12598 cells- i.v.; JJN3 HMCL cells- subcutaneous
Number Of Cells
0.5 × 10^6 for cell line 1; 5 × 10^6 for cell line 2
Image Acquisition
Instrument Vendor
ISE s.r.l.
Instrument Type
YAP-(S)-PET II
Instrument Specifics
PET- FOV of 40x40 mm
Image Acquisition Parameters
PET- 511 KeV, 30% energy resolution.
Correction
PET- isotope decay and random coincidences correction
Raw Data
Yes
QA/QC
Yes. Annual QC
Image Data
Image Type
Reconstructed and quantified images
Image Scale
KBq cc for PET
Format Compression
Raw, DICOM
Dimensions
3D
Overall Number Of Images
1 dataset per animal per time point
Field Of View
Max FOV for PET
Dimension Extents
128 x 128 x 27
Size Description
40 x 40 x 40 mm
PI xel Voxel Size Description
0,3125 x 0,3125 x 1,5 mm
Image Reconstruction Algorithm
PET- EM (30 iterations)
Quality Control
No
Image Registration Algorithm
No
Ai Enhanced Algorithm
No
Corrections
PET- acquisition decay, randoms
Image Correlation
Spatial And Temporal Alignment
No
Coregistered Images
No
Analyzed Data
Analysis Result Type
Regional increase of radiotracer's uptake
Data Used For Analysis
VOIs analysis, SUV
Analysis Method And Details
PMOD
Status
Complete
Updated Year
2022